drugset / Trial / NCT00334126
Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia
Phase 3
Completed
399 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Janssen, LP · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy (effectiveness of drug) and safety of the antipsychotic paliperidone ER compared to another antipsychotic, quetiapine, and to placebo in patients who are acutely ill with symptoms of schizophrenia.
Timeline
- Start
- 2006-04
- Primary completion
- —
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paliperidone | Unknown | 9 mg | Oral |
| Subject | Paliperidone | Unknown | 12 mg | Oral |
| Subject | Quetiapine | Small molecule | 600 mg | Oral |
| Subject | Quetiapine | Small molecule | 800 mg | Oral |